China Biologic Products Holdings, Inc. (CBPO) Company Bio
China Biologic Products engages in the research, development, manufacture, and sale of human plasma-based biopharmaceutical products to hospitals and inoculation centers in China. The company is based in Beijing, the China.
CBPO Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for China Biologic Products Holdings Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that China Biologic Products Holdings Inc ranked in the 52th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. The most interesting components of our discounted cash flow analysis for China Biologic Products Holdings Inc ended up being:
Interest coverage, a measure of earnings relative to interest payments, is 327.49 -- which is good for besting 98.65% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The business' balance sheet reveals debt to be 0% of the company's capital (with equity being the remaining amount). Approximately merely 0.05% of US stocks with free cash flow have a lower reliance on debt in their capital structure.
CBPO's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 55.86% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as CBPO, try LMAT, SNY, ACIU, EGRX, and UNH.
China Biologic Products ([[CBPO]] -1.9%) Q2 reports total sales of $111.1M (-18.1% Y/Y).Gross profit decreased by 16.0% to $76.4M.Income from operations decreased by 11.4% to $42.7M from $48.2M last year.Non-GAAP adjusted net income decreased 10.9% to $43.4M.Non-GAAP EPS of $1.11, misses consensus.In April 2020, the company received approval from the Health...
China Biologic Products Holdings, Inc. (CBPO) Q2 2020 Results Earnings Conference Call August 18, 2020, 07:30 AM ET Company Participants Philip Lisio - The Foote Group Joseph Chow - Chairman and Chief Executive Officer Ming Yin - Senior Vice President Ming Yang - Chief Financial Officer Conference Call Participants Jason...
China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today declared that the Company disagrees with the notice delivered by Xinjiang Deyuan Bioengineering Co., Ltd. ("Xinjiang Deyuan") to China Biologic, which attempts to terminate the cooperation between China Biologic and Xinjiang Deyuan, and urges Xinjiang Deyuan to cure its breaches and continue to perform its obligations under its cooperation agreement with China Biologic. In addition, the Company announced that, through the lawsuits it previously filed against Xinjiang Deyuan, the Company is seeking monetary claims totaling over RMB460 million and has obtained judicial freezing of certain s...